Dupilumab Improves Outcomes in COPD With Type 2 Inflammation

New trial confirmed safety and efficacy of a subcutaneous add-on therapy for uncontrolled COPD.

Related Keywords

United States ,Houston ,Texas ,Baylor College Of Medicine ,American ,Dharanik Narendra ,Suryap Bhatt , ,Drug Administration ,University Of Alabama At Birmingham ,American Thoracic Society ,International Conference ,New England Journal ,Triple Inhaler ,Medscape Medical ,Baylor College ,Priority Review ,